Redx Pharma Plc (LON:REDX) shares were down 2.6% on Tuesday . The stock traded as low as GBX 60.13 ($0.79) and last traded at GBX 60.13 ($0.79). Approximately 5,621 shares were traded during trading, a decline of 75% from the average daily volume of 22,585 shares. The stock had previously closed at GBX 61.75 ($0.81).
The firm’s fifty day simple moving average is GBX 63.88. The firm has a market capitalization of £172.55 million and a PE ratio of -7.28. The company has a quick ratio of 4.37, a current ratio of 4.37 and a debt-to-equity ratio of 75.02.
About Redx Pharma (LON:REDX)
Redx Pharma Plc engages in drug discovery, pre-clinical development, and licensing activities in the United Kingdom. It discovers and develops small molecule drugs for treating anti-cancer and fibrosis targets in the areas of unmet medical needs. The company is developing RXC004, a porcupine inhibitor, which has completed Phase I clinical development for the treatment of colorectal, pancreatic, biliary, and gastric cancers, as well as melanoma; ROCK inhibitor for treating inflammatory intestinal fibrosis; RXC007, a Rho-associated protein kinase 2 inhibitors for the treatment of orphan disease, idiopathic pulmonary fibrosis, non-alcoholic steatohepatitis, and other systemic fibrotic conditions; and Porcupine (RXC006), which is in Phase I for the treatment of lung fibrosis.
See Also: Municipal Bonds